Figuring out whether osteosarcoma, a rare but aggressive bone cancer that often affects children and teens, has returned or spread remains a major challenge for patients and doctors. Blood-based biomarkers, which are measurable biological signals in the body, may provide a minimally invasive way to monitor the disease, but existing methods often struggle to detect the small amounts of tumor DNA released by these bone cancers.

